Selecta Biosciences (NASDAQ: SELB)
Some price data may be temporarily unavailable.
Selecta Biosciences Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Selecta Biosciences Company Info
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.
News & Analysis
Why Selecta Biosciences Stock Is Dropping Today
The progress of one of the company's clinical programs is being delayed.
3 Top Healthcare Stocks Under $5
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Why Selecta Biosciences Tumbled 34% Today
Disappointing phase 2 data casts doubt on SEL-212's future.
About to Buy Penny Stocks? Look at These 2 Companies First
These two healthcare stocks are risky, but they have much better chances of success than penny stocks.
Here's Why Selecta Biosciences Stock Is Soaring Today
A bullish article is sending shares higher.
Here's Why Selecta Biosciences Is Tumbling Today
A licensing deal for a late-stage asset failed to impress Wall Street. One analyst went as far as downgrading the biopharma stock.
Ready for Launch: Selecta Biosciences Inc. Jumps as Much as 16%
Selecta in-licenses a promising cancer therapeutic. But don't get too carried away by today's move higher.
Valuation
Earnings Transcripts
Selecta Biosciences, Inc. (SELB) Q3 2020 Earnings Call Transcript
SELB earnings call for the period ending September 30, 2020.
Selecta Biosciences, Inc. (SELB) Q2 2020 Earnings Call Transcript
SELB earnings call for the period ending June 30, 2020.
Selecta Biosciences, Inc. (SELB) Q1 2020 Earnings Call Transcript
SELB earnings call for the period ending March 31, 2020.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.